PROTAC & Targeted Protein Degrader Deal Benchmarks
Market Analysis
Targeted protein degradation has emerged as one of the most actively partnered modalities in oncology, with PROTAC and molecular glue deals commanding significant deal values even at Phase 1. PROTAC deals achieve a median total deal value of $1.0B, with upfront payments ranging from $48M to $159M. The ability to degrade previously undruggable targets drives strong pharma interest.
Due to the early clinical stage, PROTAC deal structures are heavily weighted toward milestones. Development milestones average $364M, reflecting the extensive de-risking required around oral bioavailability, E3 ligase selectivity, and catalytic degradation efficiency. Regulatory milestones of $319M reward progress toward approval.
Royalty rates for PROTAC deals start at 8.9%-15.7% base rates, with escalation reaching 19.7% on peak sales. The 10/90 upfront/milestone split reflects the platform potential to address multiple targets beyond the initial licensed asset.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the typical total deal value for a PROTAC licensing agreement?
How are PROTAC deal milestones structured?
What differentiates high-value PROTAC deals from standard ones?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.